KAZAKH ADAPTATION OF THE MONTREAL COGNITIVE ASSESSMENT (MOCA).

The Montreal Cognitive Assessment (MoCA) is a brief cognitive evaluation tool that has been developed for screening of patients for Mild Cognitive Impairment (MCI). MCI is a recognized high-risk state for Alzheimer's disease development. The aim of the present study was to create a Kazakh-language adaptation of the original version of the Montreal Cognitive Assessment (version 7.

Establishing prognostic significance of hypoxia predictors in patients with acute cerebral pathology.

Objectives: This research aims to study the prognostic role of serum S100 as a predictor of mortality in vascular and traumatic brain injuries.

Methods: This prospective cohort study involved 219 patients. In the blood serum, neuron-specific markers (S100, NSE) and glucose, acid-base state and gas composition of arterial blood were obtained at admission, on the 3rd, 5th and 7th days of patients' stay in the intensive care unit.

[DIFFERENTIAL DIAGNOSIS AND THERAPY OF PARKONSON'S DISEASE AND ESSENTIAL TREMOR: REVIEW AND CLINICAL CASE].

At present, the problem of differential diagnosis and therapy of Parkinson's disease and essential tremor is one of the topical issues of modern clinical neurology. Despite the nosological independence of these diseases, there is evidence of their pathogenetic relationship. The article presents a review of the results of modern scientific research devoted to the study of criteria for diagnosing Parkinson's disease and essential tremor.

Neuron-Specific Markers and their Correlation with Neurological Scales in Patients with Acute Neuropathologies.

In predicting outcomes in patients with acute brain injury, current practice focuses special attention on neuron-specific proteins that reliably reflect the severity of the lesion. Further studies of molecular markers and their specificity and sensitivity could contribute to broadening the understanding of pathophysiological, diagnostic, and prognostic methods, which is vital to reducing the mortality and disability associated with these critical conditions. The purpose of this study was to assess the biomarkers of brain lesions and their correlative relations with the integral Glasgow Coma Scale (GCS) and National Institutes of Health Stroke Scale (NIHSS) in predicting severity and treatment outcomes in patients with acute neuropathologies.

[PROGNOSTIC VALUE OF BIOMARKERS OF MULTIPLE SCLEROSIS ACTIVITY].

About 30-40% of multiple sclerosis (MS) patients treated with interferon-beta (IFN-ß) develop neutralizing antibodies (NABs) to IFN-ß. NABs reduce bioavailability of IFN-ß, which leads to a decrease in the therapy effectiveness. The introduction of IFN-ß induce production of several proteins, which are used as markers of the therapy effectiveness.